Professor Matthew Kiernan

Bushell Chair of Neurology
Medicine, Central Clinical School

Telephone +61 2 9114 4250
Fax +61 2 9114 4254

Map

Biographical details

Professor Matthew Kiernan was recently appointed as the Bushell Chair of Neurology at the University of Sydney. His clinical research unit is now located at the Brain and Mind Institute. He was appointed Professor of Neurology, Royal Prince Alfred Hospital (RPAH) in 2013 and Senior Staff Specialist RPAH. He is also a Senior Scientist at Neuroscience Research Australia Professor Kiernan is the head of the Clinical Neuroscience research group comprising 20-strong team of clinicians, scientists, biomedical engineers, doctoral & postdoctoral students with focus on neurological disease. His research team's focus is clinical neurology, in particular disease pathophysiology and treatment strategies of frontotemporal dementia and motor neurone sydnromes. Currently his team is investigating the mechanisms and the possible prevention of neurodegeneration in motor neurone disease; frontotemporal dementia; chemotherapy-induced neurotoxicity; stroke; Machado-Joseph disease; spinal muscular atrophy and other inherited neuropathies. We are also involved in clinical trials investigating potential drug treatments for motor neurone disease, multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. His team's research is intrinsically linked to the provision of clinical services, particularly the ForeFront Multidisciplinary Motor Neurone Disease & Fronto temporal Dementia Clinic and diagnostic neurophysiology clinics. Professor Kiernan is the Editor-in-Chief of the Journal of Neurology, Neurosurgery and Psychiatry (BMJ Publishing Group). Professor Kiernan is Vice President of the Australian Brain Foundation, the largest priming institution for neuroscience in Australia, responsible for distributing funding towards research and medical education for the treatment and prevention of neurological disorders.

Research interests

Clinical Neurophysiology - peripheral nerve excitability and cortical nerve excitability

Frontotemporal Dementia and Motor Neurone Syndromes

  • Site of onset
  • Biomarkers
  • Mechanism of disease
  • Progression and spread of disease
  • Novel treatment strategies including regenerative medicine

ForeFront Research Pave the Way Videohttps://www.youtube.com/watch?v=F7_F8ivwT3o

[[https://www.youtube.com/watch?v=F7_F8ivwT3o|| ForeFront Research - Pave the Way Video]]

Current projects

ASSESSMENT OF NERVE AND CORTICAL EXCITABILITY IN HEREDITARY AND ACQUIRED NEUROLOGICAL DISORDERS
The aim of this study is to investigate the primary pathogenesis, development, rate of progression and magnitude of nerve degeneration in a number of hereditary and acquired neurological diseases using nerve and cortical excitability studies. Furthermore we wish to make comparisons according to clinical and genetic distinctions.

CLINICAL ASSESSMENT OF FUNCTIONAL DISABILITY IN MOTOR NEURON DISEASE
The purpose is to investigate the contributions of motor dysfunction as well as possible changes in thinking and reasoning on the performance of everyday life tasks. This project aims to assess the practical impact of Motor Neurone Disease (MND) on both patients and their family members. Cognitive ability and behavioural changes are measured in a longitudinal fashion after 6 and 12 months with the aim of investigating how these changes can affect disease progression, prognosis and provision of care. In conjunction the entire neural/motor axis in MND will be assessed using Transmagnetic Stimulation, peripheral axonal excitability studies and brain imaging techniques to examine how structural changes relate to everyday disability.

PATIENT DECISION MAKING IN MOTOR NEURON DISEASE
This study is exploring the barriers and facilitators to the delivery of patient-centred care in a terminal and progressive disease, and in chronic disease self-management. The aim of this study if to investigate what influences patients’ decision-making for symptom management and quality of life. This research is important as poorly timed decision-making impacts on MND patients’ health and quality of life.

IDENTIFYING CLINICAL MARKERS OF C9ORF72 MUTATION CARRIERS
To define the clinical, neuropsychological, behavioural and imaging features ofC9orf72mutation carries in comparison with non-carriers with the aim to identify the phenotype of the C9orf72 mutation in patients with motor neurone disease, frontotemporal dementia and FTD-MND.

BRAIN AND SPINAL CORD DONATION FOR MOTOR NEURONE DISEASE RESEARCH
In order to develop effective interventions for people with MND, more information is required on the cellular causes and how genetic variation affects the cellular mechanisms. At present the changes in the brain and spinal cord cannot be predicted by either the type of symptoms a person has, or by their genetic profile. The only way to determine the cellular changes at present is with a brain and spinal cord autopsy.
Ultimately our goal is to find a cure for MND. Our current research goal is to understand the type of cellular changes occurring in the brain and spinal cord, and by studying patients with different clinical and genetic subtypes of MND, we will be able to determine if there is a single type of change, or a variety of underlying cellular changes that will require treatment. To determine treatable cellular causes, it is essential that brain tissue be obtained to elucidate the cellular changes that are associated with the different clinical and genetic subtypes of MND.

AUSTRALIAN MOTOR NEURONE DISEASE REGISTRY
The Australian Motor Neurone Disease Registry was launched by Professor Matthew Kiernan on Motor Neurone Disease Global Awareness Day, 21 June 2005, at the Annual Conference for Health and Community CareProviders.
The Australian Motor Neurone Disease Registry is a clinical database that provides a means to facilitate the collection and analysis of Motor Neurone Disease patient data such as demographics, site of onset, diagnosis data, treatment type, changes in functional capacity, complications related to disease progression and the impact of new treatments and interventions for Motor Neurone Disease. The goals of the registry are to improve patient care through continuous evaluation of patient management and associated outcomes and to form significant scientific research collaborations with organisations and individuals to further the understanding of Motor Neurone Disease.
Visithttp://www.amndr.org for more information.

EATING, AUTONOMIC AND SEXUAL DYSFUNCTION IN FRONTOTEMPORAL DEMENTIA AND MOTOR NEURONE DISEASE
This project aims to examine the incidence and underlying causes of eating, autonomic and sexual dysfunction in motor neuron disease (MND) and frontotemporal dementia (FTD). Eating abnormalities have been well documented in FTD, this study aims to extend this work into MND. There is increasing evidence for an overlap between FTD and MND at a clinical and pathological level which has gained impetus with the recent discovery of the C9orj72 gene mutation in cases with familial FTD, FTD-MND and MND.
The term frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterised by shrinkage of the frontal and anterior temporal lobes of the brain. FTD presents with changes in personality and behaviour and/or progressive language problems. Change in eating patterns including reduced satiety, binge eating, increased carbohydrate consumption and stereotypic eating is a major criterion for the diagnosis of behavioral variant FTD. It is not known whether these same eating abnormalities are present in MND, but given the increasing evidence of an overlap, it is possible that they are. In FTD patients it has been found that those with eating abnormalities, have shrinkage of the posterior hypothalamus. The hypothalamus also controls the autonomic nervous system, which regulates internal bodily functions such as blood pressure control, stomach, bowel and urinary function. The hypothalamus is also involved in controlling sexual function. This project aims to examine the incidence of eating, autonomic and sexual symptoms in MND and FTD and by imaging methods and endocrine analysis examine the possible underlying causes and then possible interventions to reduce the impact of these symptoms on the quality of life of patients and carers.

BIOMARKERS FOR MOTOR NEURONE DISEASE
Motor Neurone Disease is an incurable neurodegenerative condition, usually resulting in death within 2-3 years of symptom onset. Currently available therapies act to prolong life expectancy only by around 3 months. This study will explore all the major pathological proteins present in body fluids in the different clinical, pathological and genetic subtypes of MND. The ultimate aim is to develop a biomarker platform for differentiating these subtypes and to track the changes in the levels of these proteins over time. The identification of biomarkers may allow early detection and characterization of MND and its pathological and genetic subtypes, and assist with monitoring future mechanistic therapies.

Associations

SENIOR NEUROLOGIST, Institute of Clinical Neurosciences, Royal Prince Alfred Hospital

EDITOR-IN-CHIEF, Journal of Neurology, Neurosurgery and Psychiatry (BMJ Publishing Group, UK)

VISITING MEDICAL OFFICER, Prince of Wales Hospital

SENIOR STAFF SPECIALIST, Prince of Wales Hospital

SENIOR PRINCIPAL RESEARCH SCIENTIST, Neuroscience Research Australia

CONJOINT PROFESSOR OF MEDICINE, Faculty of Medicine, University of New South Wales

CONSULTANT NEUROLOGIST AND NEUROPHYSIOLOGIST, Sydney Children’s Hospital

VICE PRESIDENT, Australian Brain Foundation

DIRECTOR, Motor Neurone Disease Research Institute of Australia

DIRECTOR, Neuroscience Trials Australia

MEDICAL ADVISOR, Motor Neurone Disease Association

MEDICAL ADVISOR, Muscular Dystrophy Association

MEDICAL REFERENCE GROUP, Machado Joseph Disease Foundation

MEMBER, Greater Metropolitan Transitional CareTaskforce

MEMBER, Australian and New Zealand Association of Neurologists Council

MEMBER, Australasian College of Physicians

Awards and honours

2014 Alliance Forbes Norris Award, INternational Alliance of ALS/MND
2013 Recipient RG Menzies Foundation Medal for Medical Research
2012 Inaugural Paul Brock Fellowship Award, NSW Office of Science and Medical Research, for Clinical Translation
2011 UNSW Inventor of the Year Awards 2011-runner up
2010 M.A. Brazier Prize to supervised Ph.D. student (Dr Steve Vucic, International Federation of Critical Neurophysiology)
2008 Eric Susman Prize, The Royal Australian College of Physicians
2009 2006 James G. Golseth Award, to supervised Ph.D. student (Dr Steve Vucic), American Association of Electrodiagnostic Medicine
2004 James G. Golseth Award, to supervised Ph.D. student (Dr Arun Krishnan), American Association of Electrodiagnostic Medicine
2003 Australian Physicians Independent Committee Neuroscience Award
2003 Leonard Cox Award for Excellence in Neuroscience Research, Australian and New Zealand Association of Neurologists
2002 Clinical Investigatorship, Viertel Charitable Foundation
2003 Clinical Research Award, Ramaciotti Foundation
1999-2002 CJ Martin Travelling Fellowship, National Health and Medical Research Council of Australia (top applicant in Australia)
1999-2002 RG Menzies Fellow, The Sir Robert Menzies Memorial Foundation (NHMRC Travelling Fellow)
1998 JJ Billings Overseas Travelling Fellowship, Royal Australasian College of Physicians
1998 Australian Association of Neurologists Overseas Training Position, The National Hospital for Neurology and Neurosurgery, London, UK
1997 Travelling Fellowship of the International Federation of Clinical Neurophysiology
1996 The Young Investigator Award, Annual Scientific Meeting of the Australian Association of Neurologists
1995 Royal Australasian College of Physicians NSW State Committee Advanced Trainees Award for Best Research
1995 National Health and Medical Research Council Medical Postgraduate Research Scholarship
1994 Faculty of Medicine Scholarship, University of New South Wales
1994 Whitmont Fellowship, Australian Brain Foundation

In the media

Prof Matthew Kiernan awarded Forbes Norris Awardhttps://www.mndaust.asn.au/News-and-media/Professor-Matthew-Kiernan-awarded-Forbes-Norris-Aw.aspx

ForeFront Research Pave the Way Videohttps://www.youtube.com/watch?v=F7_F8ivwT3o

Prof Kiernan welcome to University of Sydney http://sydney.edu.au/bmri/news/2013/kiernan.php

Kiernan Group page at NeuRA http://www.neura.edu.au/research/themes/kiernan-group

JNNP BMJ Twitter https://twitter.com/jnnp_bmj

Selected grants

2015

  • Motor Neuron Disease: A multidisciplinary approach to unravel the clinical phenotypes, and to improve diagnosis and management outcomes; Huynh W, Kiernan M; DVC Research/Postdoctoral Research Fellowship Scheme.

2014

  • Dementia and motor neurone disease: Extending research and translating into clinical practice; Kiernan M; Research Grant/..

2013

  • Frontotemporal dementia and motor neurodegenerative syndromes; Halliday G, Gotz J, Ittner L, Kril J, Hodges J, Kiernan M; National Health and Medical Research Council (NHMRC)/Program Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Kiernan, M., Kaji, R. (2013). Physiology and pathophysiology of myelinated nerve fibers. In Gerard Said and Christian Krarup (Eds.), Handbook of Clinical Neurology: Vol 115 Peripheral Nerve Disorders, (pp. 43-53). Amsterdam: Elsevier.
  • Vucic, S., Kiernan, M. (2013). Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. In Andres M. Lozano, Mark Hallett (Eds.), Handbook of Clinical Neurology: Brain Stimulation, (pp. 561-575). Amsterdam: Elsevier B.V.
  • Vucic, S., Burke, D., Kiernan, M. (2007). Diagnosis of Motor neuron disease. In Kiernan M (Eds.), The Motor Neurone Disease Handbook, (pp. 89-104). Strawberry Hills, Australia: Australasian Med Publ Co Ltd.
  • Vucic, S., Burke, D., Kiernan, M. (2007). Diagnosis of motor neurone disease. In Kiernan M (Eds.), The Motor Neurone Disease Handbook, (pp. 89-104). Strawberry Hills, Australia: Australasian Med Publ Co Ltd.
  • Burke, D., Lin, C., Kiernan, M., Bostock, H. (2006). Assessment of nerve excitability properties in peripheral nerve disease. In Kimura J (Eds.), Handbook of Clinical Neurophysiology, (pp. 381-403). Amsterdam: Elsevier.
  • Burke, D., Kiernan, M. (2006). Developments in the assessment of peripheral nerve function. In Kimura J (Eds.), Handbook of Clinical Neurophysiology, (pp. 927-943). Amsterdam: Elsevier.
  • Burke, D., Kiernan, M., Bostock, H. (2005). Nerve Excitability Measures: Biophysical Basis and Use in the Investigation of Peripheral Nerve Disease. In Peter J. Dyck, P.K. Thomas (Eds.), Peripheral Neuropathy, Volume 1, (pp. 113-129). Philadelphia, Pennsylvania: Saunders Elsevier.

Journals

  • Mioshi, E., Hsieh, S., Caga, J., Ramsey, E., Chen, K., Lillo, P., Simon, N., Vucic, S., Hornberger, M., Hodges, J., Kiernan, M. (2014). A novel tool to detect behavioural symptoms in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(3-4), 298-304. [More Information]
  • Ambikairajah, A., Devenney, E., Flanagan, E., Yew, B., Mioshi, E., Kiernan, M., Hodges, J., Hornberger, M. (2014). A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(3-4), 226-234. [More Information]
  • Vucic, S., Rothstein, J., Kiernan, M. (2014). Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends in Neurosciences, 37(8), 433-442. [More Information]
  • Kiernan, M. (2014). ALS and neuromuscular disease: In search of the Holy Grail. The Lancet Neurology, 13(1), 13-14. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). ALS pathophysiology: Insights from the split-hand phenomenon. Clinical Neurophysiology, 125(1), 186-193. [More Information]
  • Eisen, A., Kiernan, M., Mitsumoto, H., Swash, M. (2014). Amyotrophic lateral sclerosis: a long preclinical period? Journal of Neurology, Neurosurgery, and Psychiatry, 85(11), 1232-1238. [More Information]
  • Burrell, J., Hornberger, M., Vucic, S., Kiernan, M., Hodges, J. (2014). Apraxia and Motor Dysfunction in Corticobasal Syndrome. PloS One, 9(3), e92944. [More Information]
  • Park, S., Lin, C., Krishnan, A., Simon, N., Bostock, H., Vincent, A., Kiernan, M. (2014). Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 261, 337-342. [More Information]
  • Ahmed, R., Mioshi, E., Caga, J., Shibata, M., Zoing, M., Bartley, L., Piguet, O., Hodges, J., Kiernan, M. (2014). Body mass index delineates ALS from FTD: implications for metabolic health. Journal of Neurology, 261(9), 1774-1780. [More Information]
  • Tan, R., Devenney, E., Dobson-Stone, C., Kwok, J., Hodges, J., Kiernan, M., Halliday, G., Hornberger, M. (2014). Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PloS One, 9(8), e105632. [More Information]
  • Simon, N., Vucic, S., Joffe, R., Kiernan, M. (2014). Cortical dysfunction in cerebellar ataxia with antibodies to glutamic acid decarboxylase. Journal of Neurology, 261(1), 238-239. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). Cortical dysfunction underlies the development of the split-hand in amyotrophic lateral sclerosis. PloS One, 9(1), 1-9. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). Cortical excitability differences in hand muscles follow a split-hand pattern in healthy controls. Muscle and Nerve, 49(6), 836-844. [More Information]
  • Bae, J., Menon, P., Mioshi, E., Kiernan, M., Vucic, S. (2014). Cortical hyperexcitability and the split-hand plus phenomenon: Pathophysiological insights in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(3-4), 250-256. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). Cortical hyperexcitability of the thenar group of intrinsic hand muscles may contribute to the split-hand sign in ALS. Clinical Neurophysiology, 125(4), e1-e7. [More Information]
  • Sung, J., Tani, J., Park, S., Kiernan, M., Lin, C. (2014). Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 137(8), 2155-2163. [More Information]
  • Savage, S., Lillo, P., Kumfor, F., Kiernan, M., Piguet, O., Hodges, J. (2014). Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(1-2), 39-46. [More Information]
  • Arnold, R., Pussell, B., Howells, J., Grinius, V., Kiernan, M., Lin, C., Krishnan, A. (2014). Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clinical Neurophysiology, 125(1), 179-185. [More Information]
  • Devenney, E., Homberger, M., Irish, M., Mioshi, E., Burrell, J., Tan, R., Kiernan, M., Hodges, J. (2014). Frontotemporal Dementia Associated With the C9ORF72 Mutation A Unique Clinical Profile. JAMA Neurology, 71(3), 331-339. [More Information]
  • Bae, J., Yuki, N., Kuwabara, S., Kim, J., Vucic, S., Lin, C., Kiernan, M. (2014). Guillain-Barré syndrome in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 907-913. [More Information]
  • Mioshi, E., Caga, J., Lillo, P., Hsieh, S., Ramsey, E., Devenney, E., Hornberger, M., Hodges, J., Kiernan, M. (2014). Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology, 82(2), 149-155. [More Information]
  • Simon, N., Lomen-Hoerth, C., Kiernan, M. (2014). Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle and Nerve, 50(6), 894-899. [More Information]
  • Simon, N., Turner, M., Vucic, S., Al-Chalabi, A., Shefner, J., Lomen-Hoerth, C., Kiernan, M. (2014). Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology, 76(5), 643-657. [More Information]
  • Huynh, W., Kiernan, M. (2014). Reply: Botulinum toxin injection for post-stroke spasticity. Muscle and Nerve, 49(6), 932-933. [More Information]
  • Ahmed, R., MacMillan, M., Bartley, L., Halliday, G., Kiernan, M., Hodges, J., Piguet, O. (2014). Systemic metabolism in frontotemporal dementia. Neurology, , 1812-1818. [More Information]
  • Huynh, W., Lin, C., Krishnan, A., Vucic, S., Kiernan, M. (2014). Transynaptic changes evident in peripheral axonal function after acute cerebellar infarct. Cerebellum, 13(6), 669-676. [More Information]
  • Vucic, S., Nicholson, G., Chio, A., Kiernan, M. (2013). Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(5), 452-456. [More Information]
  • Arnold, R., Kwai, N., Lin, C., Poynten, A., Kiernan, M., Krishnan, A. (2013). Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 29(1), 53-59. [More Information]
  • Huynh, W., Krishnan, A., Lin, C., Vucic, S., Katrak, P., Hornberger, M., Kiernan, M. (2013). Botulinum Toxin Modulates Cortical Maladaptation In Post-Stroke Spasticity. Muscle and Nerve, 48(1), 93-99. [More Information]
  • Park, S., Goldstein, D., Krishnan, A., Lin, C., Friedlander, M., Cassidy, J., Koltzenburg, M., Kiernan, M. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians, 63(6), 419-437. [More Information]
  • Mioshi, E., Lillo, P., Hseih, S., Savage, S., Hodges, J., Kiernan, M., Hornberger, M. (2013). Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology, 80(12), 1117-1123. [More Information]
  • Bae, J., Menon, P., Mioshi, E., Kiernan, M., Vucic, S. (2013). Cortical excitability differences between flexor pollicis longus and APB. Neuroscience Letters, 541, 150-154. [More Information]
  • Brodtmann, A., Kiernan, M. (2013). Diagnostic shifts in ALS? From clinical specter to imaging spectra. Neurology, 80(7), 606-607. [More Information]
  • Burrell, J., Carpenter, R., Hodges, J., Kiernan, M. (2013). Early saccades in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(4), 294-301. [More Information]
  • Kwai, N., Arnold, R., Wickremaarachchi, C., Lin, C., Poynten, A., Kiernan, M., Krishnan, A. (2013). Effects of Axonal Ion Channel Dysfunction on Quality of Life in Type 2 Diabetes. Diabetes Care, 36(5), 1272-1277. [More Information]
  • Arnold, R., Pussell, B., Pianta, T., Grinius, V., Lin, C., Kiernan, M., Howells, J., Jardine, M., Krishnan, A. (2013). Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. PloS One, 8(3), 1-8. [More Information]
  • Farrar, M., Park, S., Lin, C., Kiernan, M. (2013). Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. The Journal of Physiology, 591(Pt 1), 273-286. [More Information]
  • Simon, N., Kiernan, M. (2013). Fasciculation anxiety syndrome in clinicians. Journal of Neurology, 260(7), 1743-1747. [More Information]
  • Kiernan, M. (2013). Lies, damned lies.. and citation metrics. Journal of Neurology, Neurosurgery, and Psychiatry, 84(1), 1-1. [More Information]
  • Huynh, W., Vucic, S., Krishnan, A., Lin, C., Hornberger, M., Kiernan, M. (2013). Longitudinal Plasticity Across the Neural Axis in Acute Stroke. Neurorehabilitation and Neural Repair, 27(3), 219-229. [More Information]
  • Huynh, W., Krishnan, A., Vucic, S., Lin, C., Kiernan, M. (2013). Motor Cortex Excitability in Acute Cerebellar Infarct. Cerebellum, 12(6), 826-834. [More Information]
  • Simon, N., Reddel, S., Kiernan, M., Layzer, R. (2013). Muscle-specific kinase antibodies: A novel cause of peripheral nerve hyperexcitability? Muscle and Nerve, 48(5), 819-823. [More Information]
  • Farrar, M., Vucic, S., Johnston, H., du Sart, D., Kiernan, M. (2013). Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy. The Journal of Pediatrics, 162(1), 155-159. [More Information]
  • Williams, K., Fifita, J., Vucic, S., Durnall, J., Kiernan, M., Blair, I., Nicholson, G. (2013). Pathophysiological insights into ALS with C9ORF72 expansions. Journal of Neurology, Neurosurgery, and Psychiatry, 84(8), 931-935. [More Information]
  • Vucic, S., Lin, C., Cheah, B., Murray, J., Menon, P., Krishnan, A., Kiernan, M. (2013). Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain: a journal of neurology, 136(5), 1361-1370. [More Information]
  • Menon, P., Kiernan, M., Yiannikas, C., Stroud, J., Vucic, S. (2013). Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology, 124(2), 410-416. [More Information]
  • Menon, P., Bae, J., Mioshi, E., Kiernan, M., Vucic, S. (2013). Split-hand plus sign in ALS: Differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(4), 315-318. [More Information]
  • Krishnan, A., Kiernan, M. (2013). Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 19(4), 385-391. [More Information]
  • Bae, J., Simon, N., Menon, P., Vucic, S., Kiernan, M. (2013). The Puzzling Case of Hyperexcitability in Amyotrophic Lateral Sclerosis. Journal of Clinical Neurology, 9(2), 65-74. [More Information]
  • Vucic, S., Ziemann, U., Eisen, A., Hallett, M., Kiernan, M. (2013). Transcranial magnetic stimulation and amyotrophic lateral sclerosis: Pathophysiological insights. Journal of Neurology, Neurosurgery and Psychiatry, 84(10), 1161-1170. [More Information]
  • Hogden, A., Greenfield, D., Nugus, P., Kiernan, M. (2013). What are the roles of carers in decision-making for amyotrophic lateral sclerosis multidisciplinary care? Patient Preference and Adherence, 7, 171-181. [More Information]
  • Hseih, S., Lillo, P., Kiernan, M., Hodges, J., Mioshi, E. (2013). When more is needed: the utility of the frontotemporal dementia scale in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(3), 169-171. [More Information]
  • Mioshi, E., Lillo, P., Kiernan, M., Hodges, J. (2012). Activities of daily living in motor neuron disease: role of behavioural and motor changes. Journal of Clinical Neuroscience, 19(4), 552-556. [More Information]
  • Kiernan, M. (2012). Amyotrophic lateral sclerosis and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 83(4), 355. [More Information]
  • Lillo, P., Savage, S., Mioshi, E., Kiernan, M., Hodges, J. (2012). Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 13(1), 102-109. [More Information]
  • Simon, N., Kiernan, M. (2012). Common peroneal neuropathy and cancer. Internal Medicine Journal, 42(7), 837-840. [More Information]
  • Vucic, S., Burke, T., Lenton, K., Ramanathan, S., Gomes, L., Yannikas, C., Kiernan, M. (2012). Cortical dysfunction underlies disability in multiple sclerosis. Multiple Sclerosis Journal, 18(4), 425-432. [More Information]
  • Farrar, M., Vucic, S., Johnston, H., Kiernan, M. (2012). Corticomotoneuronal Integrity and Adaptation in Spinal Muscular Atrophy. JAMA Neurology, 69(4), 467-473. [More Information]
  • Turner, M., Kiernan, M. (2012). Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 13(3), 245-250. [More Information]
  • Kiernan, M. (2012). Emergence of a predictive clinical biomarker for diabetic neuropathy. Diabetes, 61(6), 1346-1347. [More Information]
  • Hogden, A., Greenfield, D., Nugus, P., Kiernan, M. (2012). Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Preference and Adherence, 6, 691-701. [More Information]
  • Vucic, S., Stein, T., Hedley-Whyte, E., Reddel, S., Tisch, S., Kotschet, K., Cros, D., Kiernan, M. (2012). FOSMN syndrome: Novel insight into disease pathophysiology. Neurology, 79(1), 73-79. [More Information]
  • Lillo, P., Mioshi, E., Burrell, J., Kiernan, M., Hodges, J., Hornberger, M. (2012). Grey and White Matter Changes across the Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Continuum. PloS One, 7(8), 1-10. [More Information]
  • Hunter, M., Kiernan, M., Post, J. (2012). Human T-lymphotropic virus seroconversion associated with pooled human intravenous immunoglobulin therapy. Internal Medicine Journal, 42(6), 729-730. [More Information]
  • Kiernan, M., Petri, S. (2012). Hyperexcitability and amyotrophic lateral sclerosis. Neurology, 78(20), 1544-1545. [More Information]
  • Bennett, B., Park, S., Lin, C., Friedlander, M., Kiernan, M., Goldstein, D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 20(11), 2959-2967. [More Information]
  • Krishnan, A., Park, S., Huynh, W., Lin, C., Henderson, R., Kiernan, M. (2012). Impaired energy-dependent processes underlie acute lead neuropathy. Muscle and Nerve, 46(6), 954-956. [More Information]
  • Menezes, M., Waddell, L., Evesson, F., Cooper, S., Webster, R., Jones, K., Mowat, D., Kiernan, M., Johnston, H., Corbett, A., North, K., Clarke, N., et al (2012). Importance and challenge of making an early diagnosis in LMNA-related muscular dystrophy. Neurology, 78(16), 1258-1263. [More Information]
  • Tomlinson, S., Bostock, H., Grinton, B., Hanna, M., Kullmann, D., Kiernan, M., Scheffer, I., Berkovic, S., Burke, D. (2012). In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain: a journal of neurology, 135, 3144-3152. [More Information]
  • Amirjani, N., Kiernan, M., McKenzie, D., Butler, J., Gandevia, S. (2012). Is there a case for diaphragm pacing for amyotrophic lateral sclerosis patients? Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 13(6), 521-527. [More Information]
  • Park, S., Lin, C., Kiernan, M., Koltzenburg, M. (2012). Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology, 78(2), 152. [More Information]
  • Kiernan, M. (2012). Movement disorders: what lies beneath? Journal of Neurology, Neurosurgery and Psychiatry, 83(10), 949. [More Information]
  • Park, S., Lin, C., Kiernan, M. (2012). Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity. Journal of Visualized Experiments, 62, 3439. [More Information]
  • Cheah, B., Lin, C., Park, S., Vucic, S., Krishnan, A., Kiernan, M. (2012). Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 123(12), 2460-2467. [More Information]
  • Burrell, J., Homberger, M., Carpenter, R., Kiernan, M., Hodges, J. (2012). Saccadic abnormalities in frontotemporal dementia. Neurology, 78(23), 1816-1823. [More Information]
  • Kim, S., Vucic, S., Mahant, N., Kiernan, M., Fung, V. (2012). The relationship between cortical and spinal hyperexcitability and clinical disease severity in stiff-man syndrome. Parkinsonism & Related Disorders, 18(9), 1045-1047. [More Information]
  • Ahmadzai, H., Kiernan, M., Wakefield, D., Thomas, P. (2012). Treatment of refractory neurosarcoidosis with TNF-inhibitors: what lies ahead? Internal Medicine Journal, 42(2), 232. [More Information]
  • Hogden, A., Greenfield, D., Nugus, P., Kiernan, M. (2012). What influences patient decision-making in amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives. Patient Preference and Adherence, 6, 829-838. [More Information]
  • Kiernan, M. (2012). What is impact? Journal of Neurology, Neurosurgery and Psychiatry, 83(1), 1-2. [More Information]
  • Park, S., Lin, C., Burke, D., Kiernan, M. (2011). Activity-dependent conduction failure: molecular insights. Journal of the Peripheral Nervous System, 16(3), 159-168. [More Information]
  • Boland, R., Lin, C., Engel, S., Kiernan, M. (2011). Adaptation of motor function after spinal cord injury: novel insights into spinal shock. Brain: a journal of neurology, 134(2), 495-505. [More Information]
  • Kiernan, M., Vucic, S., Cheah, B., Turner, M., Eisen, A., Hardiman, O., Burrell, J., Zoing, M. (2011). Amyotrophic lateral sclerosis. The Lancet, 377(9769), 942-955. [More Information]
  • Vucic, S., Kiernan, M. (2011). Clarifying variability of corticomotoneuronal function in Kennedy disease. Muscle and Nerve, 44(2), 197-201. [More Information]
  • Hardiman, O., van den Berg, L., Kiernan, M. (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews. Neurology, 7(11), 639-649. [More Information]
  • Vucic, S., Cheah, B., Yiannikas, C., Kiernan, M. (2011). Cortical excitability distinguishes ALS from mimic disorders. Clinical Neurophysiology, 122(9), 1860-1866. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Dose effects of oxaliplatin on persistent and transient na conductances and the development of neurotoxicity. PloS One, 6(4), e18469-e18469. [More Information]
  • Farrar, M., Vucic, S., Lin, C., Park, S., Johnston, H., du Sart, D., Bostock, H., Kiernan, M. (2011). Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 134(11), 3185-3197. [More Information]
  • Park, S., Lin, C., Krishnan, A., Friedlander, M., Lewis, C., Kiernan, M. (2011). Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve, 43(3), 367-674. [More Information]
  • Kiernan, M. (2011). Freud, neurology and the emergence of dynamic neural networks. Journal of Neurology, Neurosurgery and Psychiatry, 82(2), 120. [More Information]
  • Lillo, P., Mioshi, E., Zoing, M., Kiernan, M., Hodges, J. (2011). How common are behavioural changes in amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(1), 45-51. [More Information]
  • Burrell, J., Vucic, S., Kiernan, M. (2011). Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(4), 283-289. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. The Oncologist, 16(5), 708-716. [More Information]
  • Vucic, S., Cheah, B., Kiernan, M. (2011). Maladaptation of cortical circuits underlies fatigue and weakness in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(6), 414-420. [More Information]
  • Lin, C., Krishnan, A., Park, S., Kiernan, M. (2011). Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. JAMA Neurology, 68(7), 862-869. [More Information]
  • Burrell, J., Kiernan, M., Vucic, S., Hodges, J. (2011). Motor Neuron dysfunction in frontotemporal dementia. Brain: a journal of neurology, 134(9), 2582-2594. [More Information]
  • Zoing, M., Kiernan, M. (2011). Motor neurone disease - caring for the patient in general practice. Australian Family Physician, 40(12), 962-966. [More Information]
  • Han, S., Lin, C., Boland, R., Kiernan, M. (2011). Nerve compression, membrane excitability, and symptoms of carpal tunnel syndrome. Muscle and Nerve, 44(3), 402-409. [More Information]
  • Huynh, W., Kiernan, M. (2011). Nerve conduction studies. Australian Family Physician, 40(9), 693-697. [More Information]
  • Cheah, B., Vucic, S., Krishnan, A., Boland, R., Kiernan, M. (2011). Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(1), 33-38. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2011). Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment? Journal of Clinical Oncology, 29(18), e553-e554. [More Information]
  • Burrell, J., Yiannikas, C., Rowe, D., Kiernan, M. (2011). Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PloS One, 6(10), e27041-e27041. [More Information]
  • Lin, C., Lee, M., Park, S., Kiernan, M. (2011). Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 122(12), 2336-2344. [More Information]
  • Krishnan, A., Park, S., Payne, M., Lin, C., Vucic, S., Kiernan, M. (2011). Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 122(1), 194-198. [More Information]
  • Park, S., Lin, C., Krishnan, A., Kiernan, M. (2011). The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects? Cancer Chemotherapy and Pharmacology, 67(5), 1189-1190. [More Information]
  • Huynh, W., Krishnan, A., Lin, C., Vucic, S., Kiernan, M. (2011). The effects of large artery ischemia and subsequent recanalization on nerve excitability. Muscle and Nerve, 44(5), 841. [More Information]
  • Kiernan, M. (2011). The realm of neurology - past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 82(1), 1. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Utilising natural activity to dissect the Pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 227(1), 120-127. [More Information]
  • Carson, A., Kiernan, M. (2011). Who is really the world's best known neurologist? Practical Neurology, 11(6), 380-381. [More Information]
  • Farrar, M., Lin, C., Krishnan, A., Park, S., Andrews, P., Kiernan, M. (2010). Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 126(3), e734-e739. [More Information]
  • Han, S., Lin, C., Borland, R., Bilston, L., Kiernan, M. (2010). Changes in human sensory axonal excitability induced by focal nerve compression. The Journal of Physiology, 588(10), 1737-1745. [More Information]
  • Vucic, S., Nicholson, G., Kiernan, M. (2010). Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS. Journal of Neurology, Neurosurgery and Psychiatry, 81(1), 97-100. [More Information]
  • Vucic, S., Cheah, B., Yiannikas, C., Vincent, A., Kiernan, M. (2010). Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 133(9), 2727-2733. [More Information]
  • Vucic, S., Winhammar, J., Rowe, D., Kiernan, M. (2010). Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clinical Neurophysiology, 121(10), 1781-1785. [More Information]
  • Huynh, W., Lam, A., Vucic, S., Cheah, B., Clouston, P., Kiernan, M. (2010). Corticospinal tract dysfunction and development of amyotrophic lateral sclerosis following electrical injury. Muscle and Nerve, 42(2), 288-292. [More Information]
  • Cheah, B., Kiernan, M. (2010). Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs : the investigational drugs journal, 13(12), 911-920. [More Information]
  • Vucic, S., Cheah, B., Kiernan, M. (2010). Dissecting the Mechanisms Underlying Short-Interval Intracortical Inhibition Using Exercise. Cerebral Cortex, , 1-6. [More Information]
  • Vucic, S., Burke, D., Kiernan, M. (2010). Fatigue in Multiple Sclerosis: Mechanisms and Management. Clinical Neurophysiology, 121(6), 809-817. [More Information]
  • Blair, I., Williams, K., Warraich, S., Durnall, J., Thoeng, A., Manavis, J., Blumbergs, P., Vucic, S., Kiernan, M., Nicholson, G. (2010). FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. Journal of Neurology, Neurosurgery and Psychiatry, 81(6), 639-645. [More Information]
  • Cheah, B., Kiernan, M. (2010). Neurophysiological methodologies: diagnosis of peripheral nerve disease and assessment of pharmacological agents. Current Opinion in Investigational Drugs (Print), 11(1), 72-79. [More Information]
  • Cheah, B., Vucic, S., Krishnan, A., Kiernan, M. (2010). Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis. Current Medicinal Chemistry, 17(18), 1942-1959. [More Information]
  • He, E., Wang, L., Kiernan, M. (2010). Scurvy and stroke - is there an association? Medical Journal of Australia, 193(9), 555-556. [More Information]
  • Inam, S., Vucic, S., Brodaty, N., Zoing, M., Kiernan, M. (2010). The 10-metre gait speed as a functional biomarker in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 11(6), 558-561. [More Information]
  • Loy, C., Kril, J., Trollor, J., Kiernan, M., Kwok, J., Vucic, S., Halliday, G., Hodges, J. (2010). The case of a 48 year-old woman with bizarre and complex delusions. Nature Reviews Neurology, 6(3), 175-179. [More Information]
  • Vucic, S., Kiernan, M. (2010). Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), 222-227. [More Information]
  • Kiernan, M. (2010). Why an Australian editor for JNNP? Journal of Neurology, Neurosurgery and Psychiatry, 81(1), 1-1. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27(8), 1243-1249. [More Information]
  • Kiernan, M. (2009). Amyotrophic lateral sclerosis and the neuroprotective potential of exercise. The Journal of Physiology, 587(15), 3759-3760. [More Information]
  • Boland, R., Kiernan, M. (2009). Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. Journal of Clinical Neuroscience, 16(7), 929-933. [More Information]
  • Turner, M., Kiernan, M., Leigh, P., Talbot, K. (2009). Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, 8(1), 94-109. [More Information]
  • Krishnan, A., Lin, C., Reddel, S., McGrath, R., Kiernan, M. (2009). Conduction block and impaired axonal function in tick paralysis. Muscle and Nerve, 40(3), 358-362. [More Information]
  • Nogajski, J., Kiernan, M., Ouvrier, R., Andrews, P. (2009). Congenital myasthenic syndromes. Journal of Clinical Neuroscience, 16(1), 1-11. [More Information]
  • Vucic, S., Cheah, B., Kiernan, M. (2009). Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Experimental Neurology, 220(1), 177-182. [More Information]
  • Vucic, S., Kiernan, M., Cornblath, D. (2009). Guillain-Barré syndrome: An Update. Journal of Clinical Neuroscience, 16(6), 733-741. [More Information]
  • Kiernan, M. (2009). Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. Experimental Neurology, 218(1), 1-4. [More Information]
  • Kiernan, M. (2009). Identification of cognitive deficits in amyotrophic lateral sclerosis. Clinical Neurophysiology, 120(4), 645-646. [More Information]
  • Cheah, B., Boland, R., Brodaty, N., Zoing, M., Jeffery, S., McKenzie, D., Kiernan, M. (2009). INSPIRATIonAL - INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 10(5-6), 384-392. [More Information]
  • Han, S., Boland, R., Krishnan, A., Vucic, S., Lin, C., Kiernan, M. (2009). Ischaemic sensitivity of axons in carpal tunnel syndrome. Journal of the Peripheral Nervous System, 14(3), 190-200. [More Information]
  • Barritt, A., Basci, A., Tschuchnigg, M., Sharpe, D., Kiernan, M. (2009). Myasthenia gravis seven years after removal of an invasive thymoma. Journal of Clinical Neuroscience, 16(7), 966-968. [More Information]
  • Kiernan, M., Krishnan, A. (2009). Neurological complications of chronic kidney disease. Nature Reviews. Neurology, 5(10), 542-551. [More Information]
  • Krishnan, A., Pussell, B., Kiernan, M. (2009). Neuromuscular disease in the dialysis patient: an update for the nephrologist. Seminars in Dialysis, 22(3), 267-278. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Neuro-Oncology, 77(6), 342-348. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain: a journal of neurology, 132(10), 2712-2723. [More Information]
  • Vucic, S., Kiernan, M. (2009). Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Current Molecular Medicine, 9(3), 255-272. [More Information]
  • Boland, R., Bostock, H., Kiernan, M. (2009). Plasticity of lower limb motor axons after cervical cord injury. Clinical Neurophysiology, 120(1), 204-209. [More Information]
  • Farrar, M., Johnston, H., Grattan-Smith, P., Turner, A., Kiernan, M. (2009). Spinal muscular atrophy: molecular mechanisms. Current Molecular Medicine, 9(7), 851-862. [More Information]
  • Burke, D., Howells, J., Trevillion, L., McNulty, P., Jankelowitz, S., Kiernan, M. (2009). Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. The Journal of Physiology, 587(2), 491-504. [More Information]
  • Krishnan, A., Lin, C., Kiernan, M. (2008). Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain: a journal of neurology, 131(Pt 5), 1209-1216. [More Information]
  • Nguyen-Lam, J., Kiernan, M. (2008). Acute cortical blindness due to posterior reversible encephalopathy. Journal of Clinical Neuroscience, 15(10), 1182-1185. [More Information]
  • Krishnan, A., Lin, C., Park, S., Kiernan, M. (2008). Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System, 13(1), 7-26. [More Information]
  • Krishnan, A., Bostock, H., IP, J., Hayes, M., Watson, S., Kiernan, M. (2008). Axonal function in a family with episodic ataxia type 2 due to a novel mutation. Journal of Neurology, 255(5), 750-755. [More Information]
  • Bacsi, A., Kiernan, M. (2008). Changes in axonal excitability and burst pattern behaviour in synkinesis. Journal of Clinical Neuroscience, 15(11), 1288-1290. [More Information]
  • Han, S., Boland, R., Krishnan, A., Vucic, S., Lin, C., Kiernan, M. (2008). Changes in human sensory axonal excitability induced by an ischaemic insult. Clinical Neurophysiology, 119(9), 2054-2063. [More Information]
  • Vucic, S., Kiernan, M. (2008). Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clinical Neurophysiology, 119(5), 1088-1096. [More Information]
  • Vucic, S., Nicholson, G., Kiernan, M. (2008). Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 131(6), 1540-1550. [More Information]
  • Lin, C., Krishnan, A., Lee, M., Zagami, A., You, H., Yang, C., Bostock, H., Kiernan, M. (2008). Nerve function and dysfunction in acute intermittent porphyria. Brain: a journal of neurology, 131(9), 2510-2519. [More Information]
  • Vucic, S., Kiernan, M. (2008). Normal axonal ion channel function in large peripheral nerve fibers following chronic ciguatera sensitization. Muscle and Nerve, 37(3), 403-405. [More Information]
  • Kiernan, M. (2008). Paraspinal muscles and amyotrophic lateral sclerosis - getting to the core? Clinical Neurophysiology, 119(7), 1457-1458. [More Information]
  • Stone, R., Archer, J., Kiernan, M. (2008). Wernicke's encephalopathy mimicking variant Creutzfeldt-Jakob disease. Journal of Clinical Neuroscience, 15(11), 1308-1310. [More Information]
  • Vucic, S., Kiernan, M. (2007). Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 78(8), 849-852. [More Information]
  • Lin, C., Macefield, V., Wallin, G., Elam, M., Engel, S., Kiernan, M. (2007). Axonal changes in spinal cord injured patients distal to the site of injury. Brain: a journal of neurology, 130(Pt 4), 985-994. [More Information]
  • Krishnan, A., Hayes, M., Kiernan, M. (2007). Axonal excitability properties in hemifacial spasm. Movement Disorders, 22(9), 1293-1298. [More Information]
  • Vucic, S., Kiernan, M., Krishnan, A. (2007). Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 78(11), 1202-1208. [More Information]
  • Burke, D., Howells, J., Trevillion, L., Kiernan, M., Bostock, H. (2007). Inflections in threshold electrotonus to depolarizing currents in sensory axons. Muscle and Nerve, 36(6), 849-852. [More Information]
  • Vucic, S., Kiernan, M. (2007). Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology, 69(19), 1828-1835. [More Information]
  • Hsing, J., Welgampola, M., Kiernan, M. (2007). Reversible myeloradiculopathy due to Mycoplasma pneumoniae. Journal of Clinical Neuroscience, 14(1), 61-64.
  • Hsing, J., Welgampola, M., Kiernan, M. (2007). Reversible myeloradiculopathy due to Mycoplasma pneumoniae. Journal of Clinical Neuroscience, 14(1), 61-64. [More Information]
  • Boland, R., Krishnan, A., Kiernan, M. (2007). Riche-Cannieu anastomosis as an inherited trait. Clinical Neurophysiology, 118(4), 770-775. [More Information]
  • Boland, R., Krishnan, A., Kiernan, M. (2007). Riche-Cannieu anastomosis as an inherited trait. Clinical Neurophysiology, 118(4), 770-775. [More Information]
  • Kiernan, M. (2007). The pain with platinum: oxaliplatin and neuropathy. European Journal of Cancer, 43(18), 2631-2633. [More Information]
  • Krishnan, A., Kiernan, M. (2007). Uremic neuropathy: clinical features and new pathophysiological insights. Muscle and Nerve, 35(3), 273-290. [More Information]
  • Vucic, S., Howells, J., Trevillion, L., Kiernan, M. (2006). Assessment of cortical excitability using threshold tracking techniques. Muscle and Nerve, 33(4), 477-486. [More Information]
  • Vucic, S., Kiernan, M. (2006). Axonal excitability properties in amyotrophic lateral sclerosis. Clinical Neurophysiology, 117(7), 1458-1466. [More Information]
  • Krishnan, A., Phoon, R., Pussell, B., Charlesworth, J., Bostock, H., Kiernan, M. (2006). Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain, 129(Pt 6), 1585-1592. [More Information]
  • Krishnan, A., Phoon, R., Pussell, B., Charlesworth, J., Bostock, H., Kiernan, M. (2006). Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. Clinical Neurophysiology, 117(5), 992-999. [More Information]
  • Winhammar, J., Joffe, D., Simmul, R., Schoeffel, R., Kiernan, M., Rowe, D. (2006). Nocturnal hypoxia in motor neuron disease is not predicted by standard respiratory function tests. Internal Medicine Journal, 36(7), 419-422. [More Information]
  • Vucic, S., Kiernan, M. (2006). Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 129(9), 2436-2446. [More Information]
  • Zoing, M., Burke, D., Pamphlett, R., Kiernan, M. (2006). Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). Journal of Clinical Neuroscience, 13(1), 78-83. [More Information]
  • Krishnan, A., Phoon, R., Russell, B., Charlesworth, J., Kiernan, M. (2006). Sensory nerve excitability and neuropathy in end stage kidney disease. Journal of Neurology, Neurosurgery and Psychiatry, 77(4), 548-551. [More Information]
  • Boland, R., Kiernan, M. (2005). Accuracy of the clinical assessment in diagnosis of carpal tunnel syndrome. Australian Journal of Physiotherapy, 51(4 Supplement), S12-S12.
  • Boland, R., Kiernan, M. (2005). Accuracy of the clinical diagnosis in carpal tunnel syndrome. Clinical Neurophysiology, 116(9), e21-e21.
  • Kiernan, M., Isbister, G., Lin, C., Burke, D., Bostock, H. (2005). Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Annals of Neurology, 57(3), 339-48. [More Information]
  • Krishnan, A., Phoon, R., Pussell, B., Charlesworth, J., Bostock, H., Kiernan, M. (2005). Altered motor nerve excitability in end-stage kidney disease. Brain, 128(Pt 9), 2164-2174. [More Information]
  • Winhammar, J., Rowe, D., Henderson, R., Kiernan, M. (2005). Assessment of disease progression in motor neuron disease. The Lancet Neurology, 4(4), 229-238. [More Information]
  • Boland, R., Krishnan, A., Kiernan, M. (2005). Median nerve excitability during upper limb ischaemia in patients with carpal tunnel syndrome. Australian Journal of Physiotherapy, 51(4 Supplement), S12-S12.
  • Kiernan, M., Krishnan, A., Lin, C., Burke, D., Berkovic, S. (2005). Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain, 128(8), 1841-1846. [More Information]
  • Krishnan, A., Pamphlett, R., Burke, D., Wills, E., Kiernan, M. (2004). Cytoplasmic Body Myopathy Masquerading As Motor Neuron Disease. Muscle and Nerve, 30(5), 667-672. [More Information]
  • Kiernan, M., Lin, C., Burke, D. (2004). Differences In Activity-Dependent Hyperpolarization In Human Sensory And Motor Axons. The Journal of Physiology, 558(1), 341-349.
  • Burke, D., Kiernan, M., Bostock, H. (2001). Excitability of human axons. Clinical Neurophysiology, 112(9), 1575-1585.
  • Cumming, S., Harris, L., Kiernan, M., Williams, R. (2001). Semantic Priming of Expectancies Among High-and Low-restraint Non-problem Drinkers. Australian Journal of Psychology, 53 No 3, 155-159.

Conferences

  • Menezes, M., Farrar, M., Burns, J., Menon, P., Webster, R., Antony, J., Kiernan, M., Vucic, S. (2013). Peripheral motor contributions to the pathophysiology of BVVL-related mutations in riboflavin transporter 3: Pathophysiological insights from nerve excitability testing. 2013 Meeting of the Peripheral Nerve Society, USA: Wiley-Blackwell Publishing, Inc.
  • Han, S., Lin, C., Boland, R., Kiernan, M. (2011). Effects of focal nerve compression on membrane excitability and symptoms in carpal tunnel syndrome. APA Physiotherapy Conference 2011, NA.
  • Boland, R., Kiernan, M. (2007). Accuracy Of Phalen's And Sensory Testing In Diagnosis Of Carpal Tunnel Syndrome. Proceedings of the Conference of the International Federation of Societies for Hand Therapy. IFSHT.
  • Boland, R., Han, E., Kiernan, M. (2007). Ischaemia As A Model Of Focal Nerve Injury. 15th International Congress of the World Confederation of Physical Therapy WCPT 2007, United Kingdom: Elsevier.
  • Herz, H., White, K., Butow, P., Kiernan, M. (2007). Letter on future care. 10th Congress of the European Association for Palliative Care.
  • Boland, R., Lin, C., Krishnan, A., Engel, S., Kiernan, M. (2007). Nerve Excitability Changes In Peripheral Motor Axons In Patients With Acute Spinal Injury. International Brain Research Organisation World Congress of Neuroscience.
  • Boland, R., Kiernan, M. (2007). Riche-Cannieu Anastomosis In A Family. Proceedings of the Conference of the International Federation of Societies for Hand Therapy. IFSHT.
  • Boland, R., Kiernan, M. (2006). Evidence for proximal effects on median nerve function in carpal tunnel syndrome. Life with Physiotherapy, Auckland: New Zealand Society of Physiotherapists.

2014

  • Mioshi, E., Hsieh, S., Caga, J., Ramsey, E., Chen, K., Lillo, P., Simon, N., Vucic, S., Hornberger, M., Hodges, J., Kiernan, M. (2014). A novel tool to detect behavioural symptoms in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(3-4), 298-304. [More Information]
  • Ambikairajah, A., Devenney, E., Flanagan, E., Yew, B., Mioshi, E., Kiernan, M., Hodges, J., Hornberger, M. (2014). A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(3-4), 226-234. [More Information]
  • Vucic, S., Rothstein, J., Kiernan, M. (2014). Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends in Neurosciences, 37(8), 433-442. [More Information]
  • Kiernan, M. (2014). ALS and neuromuscular disease: In search of the Holy Grail. The Lancet Neurology, 13(1), 13-14. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). ALS pathophysiology: Insights from the split-hand phenomenon. Clinical Neurophysiology, 125(1), 186-193. [More Information]
  • Eisen, A., Kiernan, M., Mitsumoto, H., Swash, M. (2014). Amyotrophic lateral sclerosis: a long preclinical period? Journal of Neurology, Neurosurgery, and Psychiatry, 85(11), 1232-1238. [More Information]
  • Burrell, J., Hornberger, M., Vucic, S., Kiernan, M., Hodges, J. (2014). Apraxia and Motor Dysfunction in Corticobasal Syndrome. PloS One, 9(3), e92944. [More Information]
  • Park, S., Lin, C., Krishnan, A., Simon, N., Bostock, H., Vincent, A., Kiernan, M. (2014). Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 261, 337-342. [More Information]
  • Ahmed, R., Mioshi, E., Caga, J., Shibata, M., Zoing, M., Bartley, L., Piguet, O., Hodges, J., Kiernan, M. (2014). Body mass index delineates ALS from FTD: implications for metabolic health. Journal of Neurology, 261(9), 1774-1780. [More Information]
  • Tan, R., Devenney, E., Dobson-Stone, C., Kwok, J., Hodges, J., Kiernan, M., Halliday, G., Hornberger, M. (2014). Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PloS One, 9(8), e105632. [More Information]
  • Simon, N., Vucic, S., Joffe, R., Kiernan, M. (2014). Cortical dysfunction in cerebellar ataxia with antibodies to glutamic acid decarboxylase. Journal of Neurology, 261(1), 238-239. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). Cortical dysfunction underlies the development of the split-hand in amyotrophic lateral sclerosis. PloS One, 9(1), 1-9. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). Cortical excitability differences in hand muscles follow a split-hand pattern in healthy controls. Muscle and Nerve, 49(6), 836-844. [More Information]
  • Bae, J., Menon, P., Mioshi, E., Kiernan, M., Vucic, S. (2014). Cortical hyperexcitability and the split-hand plus phenomenon: Pathophysiological insights in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(3-4), 250-256. [More Information]
  • Menon, P., Kiernan, M., Vucic, S. (2014). Cortical hyperexcitability of the thenar group of intrinsic hand muscles may contribute to the split-hand sign in ALS. Clinical Neurophysiology, 125(4), e1-e7. [More Information]
  • Sung, J., Tani, J., Park, S., Kiernan, M., Lin, C. (2014). Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 137(8), 2155-2163. [More Information]
  • Savage, S., Lillo, P., Kumfor, F., Kiernan, M., Piguet, O., Hodges, J. (2014). Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15(1-2), 39-46. [More Information]
  • Arnold, R., Pussell, B., Howells, J., Grinius, V., Kiernan, M., Lin, C., Krishnan, A. (2014). Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clinical Neurophysiology, 125(1), 179-185. [More Information]
  • Devenney, E., Homberger, M., Irish, M., Mioshi, E., Burrell, J., Tan, R., Kiernan, M., Hodges, J. (2014). Frontotemporal Dementia Associated With the C9ORF72 Mutation A Unique Clinical Profile. JAMA Neurology, 71(3), 331-339. [More Information]
  • Bae, J., Yuki, N., Kuwabara, S., Kim, J., Vucic, S., Lin, C., Kiernan, M. (2014). Guillain-Barré syndrome in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 907-913. [More Information]
  • Mioshi, E., Caga, J., Lillo, P., Hsieh, S., Ramsey, E., Devenney, E., Hornberger, M., Hodges, J., Kiernan, M. (2014). Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology, 82(2), 149-155. [More Information]
  • Simon, N., Lomen-Hoerth, C., Kiernan, M. (2014). Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle and Nerve, 50(6), 894-899. [More Information]
  • Simon, N., Turner, M., Vucic, S., Al-Chalabi, A., Shefner, J., Lomen-Hoerth, C., Kiernan, M. (2014). Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology, 76(5), 643-657. [More Information]
  • Huynh, W., Kiernan, M. (2014). Reply: Botulinum toxin injection for post-stroke spasticity. Muscle and Nerve, 49(6), 932-933. [More Information]
  • Ahmed, R., MacMillan, M., Bartley, L., Halliday, G., Kiernan, M., Hodges, J., Piguet, O. (2014). Systemic metabolism in frontotemporal dementia. Neurology, , 1812-1818. [More Information]
  • Huynh, W., Lin, C., Krishnan, A., Vucic, S., Kiernan, M. (2014). Transynaptic changes evident in peripheral axonal function after acute cerebellar infarct. Cerebellum, 13(6), 669-676. [More Information]

2013

  • Vucic, S., Nicholson, G., Chio, A., Kiernan, M. (2013). Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(5), 452-456. [More Information]
  • Arnold, R., Kwai, N., Lin, C., Poynten, A., Kiernan, M., Krishnan, A. (2013). Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 29(1), 53-59. [More Information]
  • Huynh, W., Krishnan, A., Lin, C., Vucic, S., Katrak, P., Hornberger, M., Kiernan, M. (2013). Botulinum Toxin Modulates Cortical Maladaptation In Post-Stroke Spasticity. Muscle and Nerve, 48(1), 93-99. [More Information]
  • Park, S., Goldstein, D., Krishnan, A., Lin, C., Friedlander, M., Cassidy, J., Koltzenburg, M., Kiernan, M. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians, 63(6), 419-437. [More Information]
  • Mioshi, E., Lillo, P., Hseih, S., Savage, S., Hodges, J., Kiernan, M., Hornberger, M. (2013). Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology, 80(12), 1117-1123. [More Information]
  • Bae, J., Menon, P., Mioshi, E., Kiernan, M., Vucic, S. (2013). Cortical excitability differences between flexor pollicis longus and APB. Neuroscience Letters, 541, 150-154. [More Information]
  • Brodtmann, A., Kiernan, M. (2013). Diagnostic shifts in ALS? From clinical specter to imaging spectra. Neurology, 80(7), 606-607. [More Information]
  • Burrell, J., Carpenter, R., Hodges, J., Kiernan, M. (2013). Early saccades in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(4), 294-301. [More Information]
  • Kwai, N., Arnold, R., Wickremaarachchi, C., Lin, C., Poynten, A., Kiernan, M., Krishnan, A. (2013). Effects of Axonal Ion Channel Dysfunction on Quality of Life in Type 2 Diabetes. Diabetes Care, 36(5), 1272-1277. [More Information]
  • Arnold, R., Pussell, B., Pianta, T., Grinius, V., Lin, C., Kiernan, M., Howells, J., Jardine, M., Krishnan, A. (2013). Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. PloS One, 8(3), 1-8. [More Information]
  • Farrar, M., Park, S., Lin, C., Kiernan, M. (2013). Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. The Journal of Physiology, 591(Pt 1), 273-286. [More Information]
  • Simon, N., Kiernan, M. (2013). Fasciculation anxiety syndrome in clinicians. Journal of Neurology, 260(7), 1743-1747. [More Information]
  • Kiernan, M. (2013). Lies, damned lies.. and citation metrics. Journal of Neurology, Neurosurgery, and Psychiatry, 84(1), 1-1. [More Information]
  • Huynh, W., Vucic, S., Krishnan, A., Lin, C., Hornberger, M., Kiernan, M. (2013). Longitudinal Plasticity Across the Neural Axis in Acute Stroke. Neurorehabilitation and Neural Repair, 27(3), 219-229. [More Information]
  • Huynh, W., Krishnan, A., Vucic, S., Lin, C., Kiernan, M. (2013). Motor Cortex Excitability in Acute Cerebellar Infarct. Cerebellum, 12(6), 826-834. [More Information]
  • Simon, N., Reddel, S., Kiernan, M., Layzer, R. (2013). Muscle-specific kinase antibodies: A novel cause of peripheral nerve hyperexcitability? Muscle and Nerve, 48(5), 819-823. [More Information]
  • Farrar, M., Vucic, S., Johnston, H., du Sart, D., Kiernan, M. (2013). Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy. The Journal of Pediatrics, 162(1), 155-159. [More Information]
  • Williams, K., Fifita, J., Vucic, S., Durnall, J., Kiernan, M., Blair, I., Nicholson, G. (2013). Pathophysiological insights into ALS with C9ORF72 expansions. Journal of Neurology, Neurosurgery, and Psychiatry, 84(8), 931-935. [More Information]
  • Menezes, M., Farrar, M., Burns, J., Menon, P., Webster, R., Antony, J., Kiernan, M., Vucic, S. (2013). Peripheral motor contributions to the pathophysiology of BVVL-related mutations in riboflavin transporter 3: Pathophysiological insights from nerve excitability testing. 2013 Meeting of the Peripheral Nerve Society, USA: Wiley-Blackwell Publishing, Inc.
  • Kiernan, M., Kaji, R. (2013). Physiology and pathophysiology of myelinated nerve fibers. In Gerard Said and Christian Krarup (Eds.), Handbook of Clinical Neurology: Vol 115 Peripheral Nerve Disorders, (pp. 43-53). Amsterdam: Elsevier.
  • Vucic, S., Lin, C., Cheah, B., Murray, J., Menon, P., Krishnan, A., Kiernan, M. (2013). Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain: a journal of neurology, 136(5), 1361-1370. [More Information]
  • Menon, P., Kiernan, M., Yiannikas, C., Stroud, J., Vucic, S. (2013). Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology, 124(2), 410-416. [More Information]
  • Menon, P., Bae, J., Mioshi, E., Kiernan, M., Vucic, S. (2013). Split-hand plus sign in ALS: Differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(4), 315-318. [More Information]
  • Krishnan, A., Kiernan, M. (2013). Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 19(4), 385-391. [More Information]
  • Bae, J., Simon, N., Menon, P., Vucic, S., Kiernan, M. (2013). The Puzzling Case of Hyperexcitability in Amyotrophic Lateral Sclerosis. Journal of Clinical Neurology, 9(2), 65-74. [More Information]
  • Vucic, S., Ziemann, U., Eisen, A., Hallett, M., Kiernan, M. (2013). Transcranial magnetic stimulation and amyotrophic lateral sclerosis: Pathophysiological insights. Journal of Neurology, Neurosurgery and Psychiatry, 84(10), 1161-1170. [More Information]
  • Vucic, S., Kiernan, M. (2013). Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. In Andres M. Lozano, Mark Hallett (Eds.), Handbook of Clinical Neurology: Brain Stimulation, (pp. 561-575). Amsterdam: Elsevier B.V.
  • Hogden, A., Greenfield, D., Nugus, P., Kiernan, M. (2013). What are the roles of carers in decision-making for amyotrophic lateral sclerosis multidisciplinary care? Patient Preference and Adherence, 7, 171-181. [More Information]
  • Hseih, S., Lillo, P., Kiernan, M., Hodges, J., Mioshi, E. (2013). When more is needed: the utility of the frontotemporal dementia scale in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(3), 169-171. [More Information]

2012

  • Mioshi, E., Lillo, P., Kiernan, M., Hodges, J. (2012). Activities of daily living in motor neuron disease: role of behavioural and motor changes. Journal of Clinical Neuroscience, 19(4), 552-556. [More Information]
  • Kiernan, M. (2012). Amyotrophic lateral sclerosis and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 83(4), 355. [More Information]
  • Lillo, P., Savage, S., Mioshi, E., Kiernan, M., Hodges, J. (2012). Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 13(1), 102-109. [More Information]
  • Simon, N., Kiernan, M. (2012). Common peroneal neuropathy and cancer. Internal Medicine Journal, 42(7), 837-840. [More Information]
  • Vucic, S., Burke, T., Lenton, K., Ramanathan, S., Gomes, L., Yannikas, C., Kiernan, M. (2012). Cortical dysfunction underlies disability in multiple sclerosis. Multiple Sclerosis Journal, 18(4), 425-432. [More Information]
  • Farrar, M., Vucic, S., Johnston, H., Kiernan, M. (2012). Corticomotoneuronal Integrity and Adaptation in Spinal Muscular Atrophy. JAMA Neurology, 69(4), 467-473. [More Information]
  • Turner, M., Kiernan, M. (2012). Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 13(3), 245-250. [More Information]
  • Kiernan, M. (2012). Emergence of a predictive clinical biomarker for diabetic neuropathy. Diabetes, 61(6), 1346-1347. [More Information]
  • Hogden, A., Greenfield, D., Nugus, P., Kiernan, M. (2012). Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Preference and Adherence, 6, 691-701. [More Information]
  • Vucic, S., Stein, T., Hedley-Whyte, E., Reddel, S., Tisch, S., Kotschet, K., Cros, D., Kiernan, M. (2012). FOSMN syndrome: Novel insight into disease pathophysiology. Neurology, 79(1), 73-79. [More Information]
  • Lillo, P., Mioshi, E., Burrell, J., Kiernan, M., Hodges, J., Hornberger, M. (2012). Grey and White Matter Changes across the Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Continuum. PloS One, 7(8), 1-10. [More Information]
  • Hunter, M., Kiernan, M., Post, J. (2012). Human T-lymphotropic virus seroconversion associated with pooled human intravenous immunoglobulin therapy. Internal Medicine Journal, 42(6), 729-730. [More Information]
  • Kiernan, M., Petri, S. (2012). Hyperexcitability and amyotrophic lateral sclerosis. Neurology, 78(20), 1544-1545. [More Information]
  • Bennett, B., Park, S., Lin, C., Friedlander, M., Kiernan, M., Goldstein, D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 20(11), 2959-2967. [More Information]
  • Krishnan, A., Park, S., Huynh, W., Lin, C., Henderson, R., Kiernan, M. (2012). Impaired energy-dependent processes underlie acute lead neuropathy. Muscle and Nerve, 46(6), 954-956. [More Information]
  • Menezes, M., Waddell, L., Evesson, F., Cooper, S., Webster, R., Jones, K., Mowat, D., Kiernan, M., Johnston, H., Corbett, A., North, K., Clarke, N., et al (2012). Importance and challenge of making an early diagnosis in LMNA-related muscular dystrophy. Neurology, 78(16), 1258-1263. [More Information]
  • Tomlinson, S., Bostock, H., Grinton, B., Hanna, M., Kullmann, D., Kiernan, M., Scheffer, I., Berkovic, S., Burke, D. (2012). In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain: a journal of neurology, 135, 3144-3152. [More Information]
  • Amirjani, N., Kiernan, M., McKenzie, D., Butler, J., Gandevia, S. (2012). Is there a case for diaphragm pacing for amyotrophic lateral sclerosis patients? Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 13(6), 521-527. [More Information]
  • Park, S., Lin, C., Kiernan, M., Koltzenburg, M. (2012). Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology, 78(2), 152. [More Information]
  • Kiernan, M. (2012). Movement disorders: what lies beneath? Journal of Neurology, Neurosurgery and Psychiatry, 83(10), 949. [More Information]
  • Park, S., Lin, C., Kiernan, M. (2012). Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity. Journal of Visualized Experiments, 62, 3439. [More Information]
  • Cheah, B., Lin, C., Park, S., Vucic, S., Krishnan, A., Kiernan, M. (2012). Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 123(12), 2460-2467. [More Information]
  • Burrell, J., Homberger, M., Carpenter, R., Kiernan, M., Hodges, J. (2012). Saccadic abnormalities in frontotemporal dementia. Neurology, 78(23), 1816-1823. [More Information]
  • Kim, S., Vucic, S., Mahant, N., Kiernan, M., Fung, V. (2012). The relationship between cortical and spinal hyperexcitability and clinical disease severity in stiff-man syndrome. Parkinsonism & Related Disorders, 18(9), 1045-1047. [More Information]
  • Ahmadzai, H., Kiernan, M., Wakefield, D., Thomas, P. (2012). Treatment of refractory neurosarcoidosis with TNF-inhibitors: what lies ahead? Internal Medicine Journal, 42(2), 232. [More Information]
  • Hogden, A., Greenfield, D., Nugus, P., Kiernan, M. (2012). What influences patient decision-making in amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives. Patient Preference and Adherence, 6, 829-838. [More Information]
  • Kiernan, M. (2012). What is impact? Journal of Neurology, Neurosurgery and Psychiatry, 83(1), 1-2. [More Information]

2011

  • Park, S., Lin, C., Burke, D., Kiernan, M. (2011). Activity-dependent conduction failure: molecular insights. Journal of the Peripheral Nervous System, 16(3), 159-168. [More Information]
  • Boland, R., Lin, C., Engel, S., Kiernan, M. (2011). Adaptation of motor function after spinal cord injury: novel insights into spinal shock. Brain: a journal of neurology, 134(2), 495-505. [More Information]
  • Kiernan, M., Vucic, S., Cheah, B., Turner, M., Eisen, A., Hardiman, O., Burrell, J., Zoing, M. (2011). Amyotrophic lateral sclerosis. The Lancet, 377(9769), 942-955. [More Information]
  • Vucic, S., Kiernan, M. (2011). Clarifying variability of corticomotoneuronal function in Kennedy disease. Muscle and Nerve, 44(2), 197-201. [More Information]
  • Hardiman, O., van den Berg, L., Kiernan, M. (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews. Neurology, 7(11), 639-649. [More Information]
  • Vucic, S., Cheah, B., Yiannikas, C., Kiernan, M. (2011). Cortical excitability distinguishes ALS from mimic disorders. Clinical Neurophysiology, 122(9), 1860-1866. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Dose effects of oxaliplatin on persistent and transient na conductances and the development of neurotoxicity. PloS One, 6(4), e18469-e18469. [More Information]
  • Farrar, M., Vucic, S., Lin, C., Park, S., Johnston, H., du Sart, D., Bostock, H., Kiernan, M. (2011). Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 134(11), 3185-3197. [More Information]
  • Park, S., Lin, C., Krishnan, A., Friedlander, M., Lewis, C., Kiernan, M. (2011). Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve, 43(3), 367-674. [More Information]
  • Han, S., Lin, C., Boland, R., Kiernan, M. (2011). Effects of focal nerve compression on membrane excitability and symptoms in carpal tunnel syndrome. APA Physiotherapy Conference 2011, NA.
  • Kiernan, M. (2011). Freud, neurology and the emergence of dynamic neural networks. Journal of Neurology, Neurosurgery and Psychiatry, 82(2), 120. [More Information]
  • Lillo, P., Mioshi, E., Zoing, M., Kiernan, M., Hodges, J. (2011). How common are behavioural changes in amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(1), 45-51. [More Information]
  • Burrell, J., Vucic, S., Kiernan, M. (2011). Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(4), 283-289. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. The Oncologist, 16(5), 708-716. [More Information]
  • Vucic, S., Cheah, B., Kiernan, M. (2011). Maladaptation of cortical circuits underlies fatigue and weakness in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(6), 414-420. [More Information]
  • Lin, C., Krishnan, A., Park, S., Kiernan, M. (2011). Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. JAMA Neurology, 68(7), 862-869. [More Information]
  • Burrell, J., Kiernan, M., Vucic, S., Hodges, J. (2011). Motor Neuron dysfunction in frontotemporal dementia. Brain: a journal of neurology, 134(9), 2582-2594. [More Information]
  • Zoing, M., Kiernan, M. (2011). Motor neurone disease - caring for the patient in general practice. Australian Family Physician, 40(12), 962-966. [More Information]
  • Han, S., Lin, C., Boland, R., Kiernan, M. (2011). Nerve compression, membrane excitability, and symptoms of carpal tunnel syndrome. Muscle and Nerve, 44(3), 402-409. [More Information]
  • Huynh, W., Kiernan, M. (2011). Nerve conduction studies. Australian Family Physician, 40(9), 693-697. [More Information]
  • Cheah, B., Vucic, S., Krishnan, A., Boland, R., Kiernan, M. (2011). Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 12(1), 33-38. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2011). Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment? Journal of Clinical Oncology, 29(18), e553-e554. [More Information]
  • Burrell, J., Yiannikas, C., Rowe, D., Kiernan, M. (2011). Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PloS One, 6(10), e27041-e27041. [More Information]
  • Lin, C., Lee, M., Park, S., Kiernan, M. (2011). Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 122(12), 2336-2344. [More Information]
  • Krishnan, A., Park, S., Payne, M., Lin, C., Vucic, S., Kiernan, M. (2011). Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 122(1), 194-198. [More Information]
  • Park, S., Lin, C., Krishnan, A., Kiernan, M. (2011). The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects? Cancer Chemotherapy and Pharmacology, 67(5), 1189-1190. [More Information]
  • Huynh, W., Krishnan, A., Lin, C., Vucic, S., Kiernan, M. (2011). The effects of large artery ischemia and subsequent recanalization on nerve excitability. Muscle and Nerve, 44(5), 841. [More Information]
  • Kiernan, M. (2011). The realm of neurology - past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 82(1), 1. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Utilising natural activity to dissect the Pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 227(1), 120-127. [More Information]
  • Carson, A., Kiernan, M. (2011). Who is really the world's best known neurologist? Practical Neurology, 11(6), 380-381. [More Information]

2010

  • Farrar, M., Lin, C., Krishnan, A., Park, S., Andrews, P., Kiernan, M. (2010). Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 126(3), e734-e739. [More Information]
  • Han, S., Lin, C., Borland, R., Bilston, L., Kiernan, M. (2010). Changes in human sensory axonal excitability induced by focal nerve compression. The Journal of Physiology, 588(10), 1737-1745. [More Information]
  • Vucic, S., Nicholson, G., Kiernan, M. (2010). Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS. Journal of Neurology, Neurosurgery and Psychiatry, 81(1), 97-100. [More Information]
  • Vucic, S., Cheah, B., Yiannikas, C., Vincent, A., Kiernan, M. (2010). Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 133(9), 2727-2733. [More Information]
  • Vucic, S., Winhammar, J., Rowe, D., Kiernan, M. (2010). Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clinical Neurophysiology, 121(10), 1781-1785. [More Information]
  • Huynh, W., Lam, A., Vucic, S., Cheah, B., Clouston, P., Kiernan, M. (2010). Corticospinal tract dysfunction and development of amyotrophic lateral sclerosis following electrical injury. Muscle and Nerve, 42(2), 288-292. [More Information]
  • Cheah, B., Kiernan, M. (2010). Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs : the investigational drugs journal, 13(12), 911-920. [More Information]
  • Vucic, S., Cheah, B., Kiernan, M. (2010). Dissecting the Mechanisms Underlying Short-Interval Intracortical Inhibition Using Exercise. Cerebral Cortex, , 1-6. [More Information]
  • Vucic, S., Burke, D., Kiernan, M. (2010). Fatigue in Multiple Sclerosis: Mechanisms and Management. Clinical Neurophysiology, 121(6), 809-817. [More Information]
  • Blair, I., Williams, K., Warraich, S., Durnall, J., Thoeng, A., Manavis, J., Blumbergs, P., Vucic, S., Kiernan, M., Nicholson, G. (2010). FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. Journal of Neurology, Neurosurgery and Psychiatry, 81(6), 639-645. [More Information]
  • Cheah, B., Kiernan, M. (2010). Neurophysiological methodologies: diagnosis of peripheral nerve disease and assessment of pharmacological agents. Current Opinion in Investigational Drugs (Print), 11(1), 72-79. [More Information]
  • Cheah, B., Vucic, S., Krishnan, A., Kiernan, M. (2010). Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis. Current Medicinal Chemistry, 17(18), 1942-1959. [More Information]
  • He, E., Wang, L., Kiernan, M. (2010). Scurvy and stroke - is there an association? Medical Journal of Australia, 193(9), 555-556. [More Information]
  • Inam, S., Vucic, S., Brodaty, N., Zoing, M., Kiernan, M. (2010). The 10-metre gait speed as a functional biomarker in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 11(6), 558-561. [More Information]
  • Loy, C., Kril, J., Trollor, J., Kiernan, M., Kwok, J., Vucic, S., Halliday, G., Hodges, J. (2010). The case of a 48 year-old woman with bizarre and complex delusions. Nature Reviews Neurology, 6(3), 175-179. [More Information]
  • Vucic, S., Kiernan, M. (2010). Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), 222-227. [More Information]
  • Kiernan, M. (2010). Why an Australian editor for JNNP? Journal of Neurology, Neurosurgery and Psychiatry, 81(1), 1-1. [More Information]

2009

  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27(8), 1243-1249. [More Information]
  • Kiernan, M. (2009). Amyotrophic lateral sclerosis and the neuroprotective potential of exercise. The Journal of Physiology, 587(15), 3759-3760. [More Information]
  • Boland, R., Kiernan, M. (2009). Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. Journal of Clinical Neuroscience, 16(7), 929-933. [More Information]
  • Turner, M., Kiernan, M., Leigh, P., Talbot, K. (2009). Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, 8(1), 94-109. [More Information]
  • Krishnan, A., Lin, C., Reddel, S., McGrath, R., Kiernan, M. (2009). Conduction block and impaired axonal function in tick paralysis. Muscle and Nerve, 40(3), 358-362. [More Information]
  • Nogajski, J., Kiernan, M., Ouvrier, R., Andrews, P. (2009). Congenital myasthenic syndromes. Journal of Clinical Neuroscience, 16(1), 1-11. [More Information]
  • Vucic, S., Cheah, B., Kiernan, M. (2009). Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Experimental Neurology, 220(1), 177-182. [More Information]
  • Vucic, S., Kiernan, M., Cornblath, D. (2009). Guillain-Barré syndrome: An Update. Journal of Clinical Neuroscience, 16(6), 733-741. [More Information]
  • Kiernan, M. (2009). Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. Experimental Neurology, 218(1), 1-4. [More Information]
  • Kiernan, M. (2009). Identification of cognitive deficits in amyotrophic lateral sclerosis. Clinical Neurophysiology, 120(4), 645-646. [More Information]
  • Cheah, B., Boland, R., Brodaty, N., Zoing, M., Jeffery, S., McKenzie, D., Kiernan, M. (2009). INSPIRATIonAL - INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 10(5-6), 384-392. [More Information]
  • Han, S., Boland, R., Krishnan, A., Vucic, S., Lin, C., Kiernan, M. (2009). Ischaemic sensitivity of axons in carpal tunnel syndrome. Journal of the Peripheral Nervous System, 14(3), 190-200. [More Information]
  • Barritt, A., Basci, A., Tschuchnigg, M., Sharpe, D., Kiernan, M. (2009). Myasthenia gravis seven years after removal of an invasive thymoma. Journal of Clinical Neuroscience, 16(7), 966-968. [More Information]
  • Kiernan, M., Krishnan, A. (2009). Neurological complications of chronic kidney disease. Nature Reviews. Neurology, 5(10), 542-551. [More Information]
  • Krishnan, A., Pussell, B., Kiernan, M. (2009). Neuromuscular disease in the dialysis patient: an update for the nephrologist. Seminars in Dialysis, 22(3), 267-278. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Neuro-Oncology, 77(6), 342-348. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain: a journal of neurology, 132(10), 2712-2723. [More Information]
  • Vucic, S., Kiernan, M. (2009). Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Current Molecular Medicine, 9(3), 255-272. [More Information]
  • Boland, R., Bostock, H., Kiernan, M. (2009). Plasticity of lower limb motor axons after cervical cord injury. Clinical Neurophysiology, 120(1), 204-209. [More Information]
  • Farrar, M., Johnston, H., Grattan-Smith, P., Turner, A., Kiernan, M. (2009). Spinal muscular atrophy: molecular mechanisms. Current Molecular Medicine, 9(7), 851-862. [More Information]
  • Burke, D., Howells, J., Trevillion, L., McNulty, P., Jankelowitz, S., Kiernan, M. (2009). Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. The Journal of Physiology, 587(2), 491-504. [More Information]

2008

  • Krishnan, A., Lin, C., Kiernan, M. (2008). Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain: a journal of neurology, 131(Pt 5), 1209-1216. [More Information]
  • Nguyen-Lam, J., Kiernan, M. (2008). Acute cortical blindness due to posterior reversible encephalopathy. Journal of Clinical Neuroscience, 15(10), 1182-1185. [More Information]
  • Krishnan, A., Lin, C., Park, S., Kiernan, M. (2008). Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System, 13(1), 7-26. [More Information]
  • Krishnan, A., Bostock, H., IP, J., Hayes, M., Watson, S., Kiernan, M. (2008). Axonal function in a family with episodic ataxia type 2 due to a novel mutation. Journal of Neurology, 255(5), 750-755. [More Information]
  • Bacsi, A., Kiernan, M. (2008). Changes in axonal excitability and burst pattern behaviour in synkinesis. Journal of Clinical Neuroscience, 15(11), 1288-1290. [More Information]
  • Han, S., Boland, R., Krishnan, A., Vucic, S., Lin, C., Kiernan, M. (2008). Changes in human sensory axonal excitability induced by an ischaemic insult. Clinical Neurophysiology, 119(9), 2054-2063. [More Information]
  • Vucic, S., Kiernan, M. (2008). Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clinical Neurophysiology, 119(5), 1088-1096. [More Information]
  • Vucic, S., Nicholson, G., Kiernan, M. (2008). Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 131(6), 1540-1550. [More Information]
  • Lin, C., Krishnan, A., Lee, M., Zagami, A., You, H., Yang, C., Bostock, H., Kiernan, M. (2008). Nerve function and dysfunction in acute intermittent porphyria. Brain: a journal of neurology, 131(9), 2510-2519. [More Information]
  • Vucic, S., Kiernan, M. (2008). Normal axonal ion channel function in large peripheral nerve fibers following chronic ciguatera sensitization. Muscle and Nerve, 37(3), 403-405. [More Information]
  • Kiernan, M. (2008). Paraspinal muscles and amyotrophic lateral sclerosis - getting to the core? Clinical Neurophysiology, 119(7), 1457-1458. [More Information]
  • Stone, R., Archer, J., Kiernan, M. (2008). Wernicke's encephalopathy mimicking variant Creutzfeldt-Jakob disease. Journal of Clinical Neuroscience, 15(11), 1308-1310. [More Information]

2007

  • Vucic, S., Kiernan, M. (2007). Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 78(8), 849-852. [More Information]
  • Boland, R., Kiernan, M. (2007). Accuracy Of Phalen's And Sensory Testing In Diagnosis Of Carpal Tunnel Syndrome. Proceedings of the Conference of the International Federation of Societies for Hand Therapy. IFSHT.
  • Lin, C., Macefield, V., Wallin, G., Elam, M., Engel, S., Kiernan, M. (2007). Axonal changes in spinal cord injured patients distal to the site of injury. Brain: a journal of neurology, 130(Pt 4), 985-994. [More Information]
  • Krishnan, A., Hayes, M., Kiernan, M. (2007). Axonal excitability properties in hemifacial spasm. Movement Disorders, 22(9), 1293-1298. [More Information]
  • Vucic, S., Burke, D., Kiernan, M. (2007). Diagnosis of Motor neuron disease. In Kiernan M (Eds.), The Motor Neurone Disease Handbook, (pp. 89-104). Strawberry Hills, Australia: Australasian Med Publ Co Ltd.
  • Vucic, S., Burke, D., Kiernan, M. (2007). Diagnosis of motor neurone disease. In Kiernan M (Eds.), The Motor Neurone Disease Handbook, (pp. 89-104). Strawberry Hills, Australia: Australasian Med Publ Co Ltd.
  • Vucic, S., Kiernan, M., Krishnan, A. (2007). Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 78(11), 1202-1208. [More Information]
  • Burke, D., Howells, J., Trevillion, L., Kiernan, M., Bostock, H. (2007). Inflections in threshold electrotonus to depolarizing currents in sensory axons. Muscle and Nerve, 36(6), 849-852. [More Information]
  • Boland, R., Han, E., Kiernan, M. (2007). Ischaemia As A Model Of Focal Nerve Injury. 15th International Congress of the World Confederation of Physical Therapy WCPT 2007, United Kingdom: Elsevier.
  • Herz, H., White, K., Butow, P., Kiernan, M. (2007). Letter on future care. 10th Congress of the European Association for Palliative Care.
  • Boland, R., Lin, C., Krishnan, A., Engel, S., Kiernan, M. (2007). Nerve Excitability Changes In Peripheral Motor Axons In Patients With Acute Spinal Injury. International Brain Research Organisation World Congress of Neuroscience.
  • Vucic, S., Kiernan, M. (2007). Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology, 69(19), 1828-1835. [More Information]
  • Hsing, J., Welgampola, M., Kiernan, M. (2007). Reversible myeloradiculopathy due to Mycoplasma pneumoniae. Journal of Clinical Neuroscience, 14(1), 61-64.
  • Hsing, J., Welgampola, M., Kiernan, M. (2007). Reversible myeloradiculopathy due to Mycoplasma pneumoniae. Journal of Clinical Neuroscience, 14(1), 61-64. [More Information]
  • Boland, R., Krishnan, A., Kiernan, M. (2007). Riche-Cannieu anastomosis as an inherited trait. Clinical Neurophysiology, 118(4), 770-775. [More Information]
  • Boland, R., Krishnan, A., Kiernan, M. (2007). Riche-Cannieu anastomosis as an inherited trait. Clinical Neurophysiology, 118(4), 770-775. [More Information]
  • Boland, R., Kiernan, M. (2007). Riche-Cannieu Anastomosis In A Family. Proceedings of the Conference of the International Federation of Societies for Hand Therapy. IFSHT.
  • Kiernan, M. (2007). The pain with platinum: oxaliplatin and neuropathy. European Journal of Cancer, 43(18), 2631-2633. [More Information]
  • Krishnan, A., Kiernan, M. (2007). Uremic neuropathy: clinical features and new pathophysiological insights. Muscle and Nerve, 35(3), 273-290. [More Information]

2006

  • Vucic, S., Howells, J., Trevillion, L., Kiernan, M. (2006). Assessment of cortical excitability using threshold tracking techniques. Muscle and Nerve, 33(4), 477-486. [More Information]
  • Burke, D., Lin, C., Kiernan, M., Bostock, H. (2006). Assessment of nerve excitability properties in peripheral nerve disease. In Kimura J (Eds.), Handbook of Clinical Neurophysiology, (pp. 381-403). Amsterdam: Elsevier.
  • Vucic, S., Kiernan, M. (2006). Axonal excitability properties in amyotrophic lateral sclerosis. Clinical Neurophysiology, 117(7), 1458-1466. [More Information]
  • Burke, D., Kiernan, M. (2006). Developments in the assessment of peripheral nerve function. In Kimura J (Eds.), Handbook of Clinical Neurophysiology, (pp. 927-943). Amsterdam: Elsevier.
  • Boland, R., Kiernan, M. (2006). Evidence for proximal effects on median nerve function in carpal tunnel syndrome. Life with Physiotherapy, Auckland: New Zealand Society of Physiotherapists.
  • Krishnan, A., Phoon, R., Pussell, B., Charlesworth, J., Bostock, H., Kiernan, M. (2006). Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain, 129(Pt 6), 1585-1592. [More Information]
  • Krishnan, A., Phoon, R., Pussell, B., Charlesworth, J., Bostock, H., Kiernan, M. (2006). Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. Clinical Neurophysiology, 117(5), 992-999. [More Information]
  • Winhammar, J., Joffe, D., Simmul, R., Schoeffel, R., Kiernan, M., Rowe, D. (2006). Nocturnal hypoxia in motor neuron disease is not predicted by standard respiratory function tests. Internal Medicine Journal, 36(7), 419-422. [More Information]
  • Vucic, S., Kiernan, M. (2006). Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 129(9), 2436-2446. [More Information]
  • Zoing, M., Burke, D., Pamphlett, R., Kiernan, M. (2006). Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). Journal of Clinical Neuroscience, 13(1), 78-83. [More Information]
  • Krishnan, A., Phoon, R., Russell, B., Charlesworth, J., Kiernan, M. (2006). Sensory nerve excitability and neuropathy in end stage kidney disease. Journal of Neurology, Neurosurgery and Psychiatry, 77(4), 548-551. [More Information]

2005

  • Boland, R., Kiernan, M. (2005). Accuracy of the clinical assessment in diagnosis of carpal tunnel syndrome. Australian Journal of Physiotherapy, 51(4 Supplement), S12-S12.
  • Boland, R., Kiernan, M. (2005). Accuracy of the clinical diagnosis in carpal tunnel syndrome. Clinical Neurophysiology, 116(9), e21-e21.
  • Kiernan, M., Isbister, G., Lin, C., Burke, D., Bostock, H. (2005). Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Annals of Neurology, 57(3), 339-48. [More Information]
  • Krishnan, A., Phoon, R., Pussell, B., Charlesworth, J., Bostock, H., Kiernan, M. (2005). Altered motor nerve excitability in end-stage kidney disease. Brain, 128(Pt 9), 2164-2174. [More Information]
  • Winhammar, J., Rowe, D., Henderson, R., Kiernan, M. (2005). Assessment of disease progression in motor neuron disease. The Lancet Neurology, 4(4), 229-238. [More Information]
  • Boland, R., Krishnan, A., Kiernan, M. (2005). Median nerve excitability during upper limb ischaemia in patients with carpal tunnel syndrome. Australian Journal of Physiotherapy, 51(4 Supplement), S12-S12.
  • Kiernan, M., Krishnan, A., Lin, C., Burke, D., Berkovic, S. (2005). Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain, 128(8), 1841-1846. [More Information]
  • Burke, D., Kiernan, M., Bostock, H. (2005). Nerve Excitability Measures: Biophysical Basis and Use in the Investigation of Peripheral Nerve Disease. In Peter J. Dyck, P.K. Thomas (Eds.), Peripheral Neuropathy, Volume 1, (pp. 113-129). Philadelphia, Pennsylvania: Saunders Elsevier.

2004

  • Krishnan, A., Pamphlett, R., Burke, D., Wills, E., Kiernan, M. (2004). Cytoplasmic Body Myopathy Masquerading As Motor Neuron Disease. Muscle and Nerve, 30(5), 667-672. [More Information]
  • Kiernan, M., Lin, C., Burke, D. (2004). Differences In Activity-Dependent Hyperpolarization In Human Sensory And Motor Axons. The Journal of Physiology, 558(1), 341-349.

2001

  • Burke, D., Kiernan, M., Bostock, H. (2001). Excitability of human axons. Clinical Neurophysiology, 112(9), 1575-1585.
  • Cumming, S., Harris, L., Kiernan, M., Williams, R. (2001). Semantic Priming of Expectancies Among High-and Low-restraint Non-problem Drinkers. Australian Journal of Psychology, 53 No 3, 155-159.

To update your profile click here. For support on your academic profile contact .